Total Cancer Incidence and Overall Mortality Are Not Increased Among Patients With Barrett's Esophagus

Schouten, Leo J.; Steevens, Jessie; Huysentruyt, Clément J.R.; Coffeng, Ceciel E.; Keulemans, Yolande C.A.; Leeuwen, F.E. van; Driessen, Ann; Brandt, Piet A. van den

doi:10.1016/j.cgh.2011.04.008

Cited by 42 publications

(33 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ten studies were considered to be of the highest quality in that they had no evidence of selection bias, more than 5 years of mean follow-up and at least 1 year of minimum follow-up 4 65 66 74 76 79 84 95 110 111. These comprised 3345 patients and 23 984 patient-years of follow-up.…”

Section: Resultsmentioning

confidence: 99%

The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis

Desai

Krishnan

Samala

et al. 2011

Gut

537

352

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis

Desai

Krishnan

Samala

et al. 2011

Gut

537

352

View full text Add to dashboard Cite

show abstract

“…[26][27][28] Schouten et al, 26 in a population-based cohort of 605 patients, reported 2.1% mortality related to EAC. Caygill et al, 27 in their 3 decades of experience at a single center, reported 3.9% mortality from EAC in 1175 patients.…”

Section: Discussionmentioning

confidence: 99%

Low risk of adenocarcinoma and high-grade dysplasia in patients with non-dysplastic Barrett’s esophagus: Results from a cohort from a country with low esophageal adenocarcinoma incidence

Pereira

Chaves

2015

United European Gastroenterology Journal

View full text Add to dashboard Cite

Background: The risk of esophageal adenocarcinoma (EAC) in non-dysplastic Barrett's esophagus (NDBE) is considered to be approximately 0.3% per year or even lower, according to population-based studies. Data from countries with low EAC incidence are scarce. Our principal aim was to determine the incidence of high-grade dysplasia (HGD) and EAC in NDBE. Our secondary aims were to identify the predictors of progression and to calculate the incidence of HGD/EAC, by using the calculation method for surveillance time in population-based studies. Materials and methods: A cohort of NDBE patients was prospectively followed up. Cases of HGD and EAC (study end points) diagnosed during the first year of follow-up were considered as prevalent. Only cases with an endoscopic surveillance time > 1 year were included in our analysis. Results: We enrolled 331 patients (251 men) in the surveillance program. Their median age was 59 years (interquartile range (IQR): 47-67 years). Their median NDBE length was 3 cm (IQR: 2-4 cm). Of these patients, 80 died during the follow-up (one from EAC) and two were lost to follow-up. After 2284 patient-years of endoscopic follow-up (median surveillance time, 5 years (IQR: 2-10 years)), we found that five cases of HGD and two cases of EAC were diagnosed. The incidence of HGD/EAC was 3.1 cases per 1000 patient-years (95% CI: 1.3-6.0) and that of EAC was 0.9 (95% CI: 0.2-2.9). The incidence of HGD/EAC in short segments ( 3 cm) was 0.7 cases per 1000 patient-years (95% CI: 0.3-3.4). The sole variable that we found associated with progression was NDBE length. If the total surveillance time was considered (3537 patient-years), the incidence of HGD and EAC was only slight lower. Conclusions: The incidence of HGD and EAC was very low in NDBE. Therefore, current surveillance guidelines must be reassessed, at least for short-segment BE.

show abstract

“…By the other hand, even when BE is diagnosed, a vast majority of these patients will not develop EAC during their lifetime [10]. Studies have shown that the overall mortality rate in patients with BE is closely similar to that of the general population and EAC mortality is an uncommon cause of death in these patients [103,104]. The most patients with BE die due to causes other than EAC.…”

Section: Screening For Bementioning

confidence: 99%

Diagnosis and Management of Barrett’s Esophagus with and Without Dysplasia

Vladimirov¹,

Ivanova²,

Terziev³

2013

Endoscopy of GI Tract

View full text Add to dashboard Cite

Total Cancer Incidence and Overall Mortality Are Not Increased Among Patients With Barrett's Esophagus

Cited by 42 publications

References 26 publications

The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis

The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis

Low risk of adenocarcinoma and high-grade dysplasia in patients with non-dysplastic Barrett’s esophagus: Results from a cohort from a country with low esophageal adenocarcinoma incidence

Diagnosis and Management of Barrett’s Esophagus with and Without Dysplasia

Contact Info

Product

Resources

About